In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Saved in:
| Title: | In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma. |
|---|---|
| Authors: | Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO 80218, USA., Costello CL; Department of Medicine, Division of Blood & Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Birhiray RE; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN 46260, USA., Kambhampati S; Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA., Richter J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Stokes M; Evidera, Data Analytics, St-Laurent, Quebec, H4T 1V6, Canada., Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Bogard K; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Noga SJ; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Girnius S; TriHealth Cancer Institute, Cincinnati, OH 45247, USA. |
| Source: | Future oncology (London, England) [Future Oncol] 2024 Jan; Vol. 20 (3), pp. 131-143. Date of Electronic Publication: 2023 Oct 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
